# US 12,006,504 B2 · Production of DHA and other LC PUFAs in plants

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,006,504 B2
- Document ID: US12006504B2
- Status: Granted
- Kind: B2
- Application number: 17/669,945
- Filed: 2022-02-11
- Published: 2022-06-02
- Granted: 2024-06-11
- Earliest claimed: 2010-05-17
- Assignees: Dsm IP Assets B.V.; Dow AgroSciences LLC
- Applicants: DSM IP Assets B.V.; DOW AgroSciences LLC
- Inventors: Terence A. Walsh; Daniel Gachotte; Ann Owens Merlo; Paul G. Roessler; James George Metz; Scott Bevan; Jerry M. Kuner
- Web page: https://patentgrep.com/patent/US12006504B2

## CPC

- C12N 15/8247: {involving modified lipid metabolism, e.g. seed oil composition}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 3/06: Antihyperlipidemics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/24: Antidepressants
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C12P 7/6427: Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
- C12P 7/6432: Eicosapentaenoic acids [EPA]
- C12P 7/6434: Docosahexenoic acids [DHA]
- C12N 9/1029: {transferring groups other than amino-acyl groups (2.3.1)}
- C12N 9/1288: {Transferases for other substituted phosphate groups (2.7.8)}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

The invention provides recombinant host organisms (e.g., plants) genetically modified with a polyunsaturated fatty acid (PUFA) synthase system and one or more accessory proteins (e.g., PPTase and/or ACoAS) that allow for and/or improve the production of PUFAs in the host organism. The present invention also relates to methods of making and using such organisms (e.g., to obtain PUFAs) as well as products obtained from such organisms (e.g., oil and/or seed).

## Claims

### Claim 1

A method of obtaining a canola seed oil comprising the step of extracting a canola seed oil from a genetically modified Brassica plant, said genetically modified Brassica plant being genetically modified to express a PUFA synthase system derived from a eukaryotic source, the canola seed oil comprising at least 0.01% docosahexaenoic acid (DHA), wherein said canola seed oil is of the intermediate or side products of gamma-linolenic acid (GLA; 18:3, n-6), stearidonic acid (STA or SDA; 18:4, n-3), dihomo-gamma-linolenic acid (DGLA or HGLA; 20:3, n-6), arachidonic acid (ARA, C20:4, n-6), and eicosatrienoic acid (ETA; 20:3, n-9), so long as such intermediate or side products are not naturally produced by the endogenous FAS system in the wild-type canola plant.

### Claim 2 (depends on 1)

The method of claim 1, wherein said canola seed oil comprises less than 7% by weight of total fatty acids of intermediate or side products.

### Claim 3 (depends on 1)

The method of claim 1, wherein said canola seed oil comprises less than 5% by weight of total fatty acids of intermediate or side products.

### Claim 4 (depends on 1)

The method of claim 1, wherein said canola seed oil comprises less than 3% by weight of total fatty acids of intermediate or side products.

### Claim 5 (depends on 1)

The method of claim 1, wherein said intermediate or side products further comprises 20:0, 20:1 (Δ5), 20:1 (Δ11), 20:2 (Δ8,11), 20:2 (Δ11,14), 20:3 (Δ5,11,14), 20:3 (Δ11,14,17), mead acid (20:3; Δ5,8,11), and 20:4 (Δ5,1,14,17).

### Claim 6 (depends on 5)

The method of claim 5, wherein said canola seed oil comprises less than 7% by weight of total fatty acids of intermediate or side products.

### Claim 7 (depends on 5)

The method of claim 5, wherein said canola seed oil comprises less than 5% by weight of total fatty acids of intermediate or side products.

### Claim 8 (depends on 5)

The method of claim 5, wherein said canola seed oil comprises less than 3% by weight of total fatty acids of intermediate or side products.

### Claim 9 (depends on 1)

The method of claim 1, wherein said canola seed oil comprises 0.01% to 5% EPA.

### Claim 10 (depends on 1)

The method of claim 1, wherein said canola seed oil comprises 0.05% to 1% EPA.

### Claim 11 (depends on 8)

The method of claim 8, wherein said canola seed oil comprises 0.05% to 1% EPA.

### Claim 12 (depends on 1)

The method of claim 1, wherein said canola seed oil comprises DHA and DPA, wherein the proportion of DHA is at least 70% by weight of the total amount of DHA and DPA.

### Claim 13 (depends on 1)

The method of claim 1, wherein said canola seed oil comprises EPA, wherein the proportion of DHA is at least 70% by weight of the total amount of DHA, DPA and EPA.

### Claim 14 (depends on 1)

The method of claim 1, wherein said canola seed oil comprises DHA and 0.05% to 1% EPA, wherein the proportion of DHA is at least 70% by weight of the total amount of DHA, DPA and EPA.

### Claim 15 (depends on 8)

The method of claim 8, wherein said canola seed oil comprises DHA and 0.05% to 1% EPA, wherein the proportion of DHA is at least 70% by weight of the total amount of DHA, DPA and EPA.